Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria (clinicaltrials.gov) - Oct 3, 2022 - P1 | N=32 | Not yet recruiting | Sponsor: United BioPharma | Trial completion date: Jan 2024 ➔ Jan 2026 | Trial primary completion date: Nov 2022 ➔ Nov 2024
Trial completion date • Trial primary completion date • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|